Patents Represented by Attorney Leslie Fischer
-
Patent number: 8282922Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand-IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: GrantFiled: May 28, 2008Date of Patent: October 9, 2012Assignee: Novartis AGInventors: Hermann Gram, Thomas Jung
-
Patent number: 8273350Abstract: An IL-1? binding molecule, in particular an antibody to human IL-1?, especially a human antibody to human IL-1? is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.Type: GrantFiled: June 29, 2011Date of Patent: September 25, 2012Assignee: Novartis AGInventors: Hermann Gram, Franco E Di Padova
-
Patent number: 8252310Abstract: The present invention relates to a new iron containing phosphate adsorbent and its use e.g. for treating hyperphosphataemia.Type: GrantFiled: December 10, 2007Date of Patent: August 28, 2012Assignee: Novartis AGInventors: Michael Ambühl, Corine Gessier-Vial, Christa Hartmann, Daniel Kaufmann, Ernst Küsters, Ulrich Meier, Andreas Meyer, Nabila Sekkat
-
Patent number: 8246953Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.Type: GrantFiled: November 11, 2010Date of Patent: August 21, 2012Assignee: Novartis AGInventors: Michaela Kniessel, Christine Halleux, Shou-Ih Hu, Beate Diefenbach-Streiber, Josef Prassler
-
Patent number: 8119131Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: February 18, 2010Date of Patent: February 21, 2012Assignee: Novartis AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8105587Abstract: This invention relates to methods employing IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand-IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: GrantFiled: October 24, 2006Date of Patent: January 31, 2012Assignees: Novartis AG, Novartis Pharma GmbHInventors: Phil Lowe, Hermann Gram, Thomas Jung, Timothy Wright, Trevor Mundel
-
Patent number: 8076160Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.Type: GrantFiled: September 26, 2008Date of Patent: December 13, 2011Assignee: Novartis AGInventors: Patrick Albientz, Jean-Michel Grenet, Rainer Hillenbrand, Francois Legay, Peter Marbach, Severine Marrony, Judith Schaefer
-
Patent number: 8012477Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of a solid or hematological malignant diseases.Type: GrantFiled: January 30, 2007Date of Patent: September 6, 2011Assignees: Novartis AG, Novartis Pharma GmbHInventors: Michael Cooreman, Franco E. Di Padova
-
Patent number: 8008511Abstract: A process for modifying the crystal habit of acicular drug substances, crystals obtained by such a process, and particular crystal forms or modifications of mycophenolic acid or mycophenolate sodium are provided, as well as pharmaceutical compositions comprising the crystals, methods of treatment and uses thereof.Type: GrantFiled: December 18, 2008Date of Patent: August 30, 2011Assignee: Novartis AGInventors: Sabine Pfeffer, Dierk Wieckhusen
-
Patent number: 7998687Abstract: The invention relates to the analysis and identification of genes that are modulated in transplant rejection. This alteration of gene expression provides a molecular signature to accurately detect transplant rejection.Type: GrantFiled: April 19, 2007Date of Patent: August 16, 2011Assignees: Novartis AG, Novartis Pharma GmbHInventor: Peter Grass
-
Patent number: 7993878Abstract: An IL-1? binding molecule, in particular an antibody to human IL-1?, especially a human antibody to human IL-1? is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.Type: GrantFiled: September 26, 2008Date of Patent: August 9, 2011Assignee: Novartis AGInventors: Hermann Gram, Franco E Di Padova
-
Patent number: 7968518Abstract: Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g., of formula (I, Ia or II) as defined herein, having useful properties in the prevention of Hepatitis C infections.Type: GrantFiled: September 2, 2004Date of Patent: June 28, 2011Assignee: Novartis AGInventors: Makoto Hijikata, Kunitada Shimotohno, Koichi Watashi
-
Patent number: 7932241Abstract: A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.Type: GrantFiled: September 17, 2004Date of Patent: April 26, 2011Assignee: Novartis AGInventors: Alexandra Glausch, Rolf Löffler, Juergen Sigg
-
Patent number: 7906677Abstract: A process for the production of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula II wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of Formula I are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase II.Type: GrantFiled: May 7, 2009Date of Patent: March 15, 2011Assignee: Novartis AGInventors: Murat Acemoglu, Thomas Allmendinger, John Vincent Calienni, Jacques Cercus, Olivier Loiseleur, Gottfried Sedelmeier, David Xu
-
Patent number: 7897565Abstract: The present invention concerns a pharmaceutical combination comprising a) a first agent which is a non-immunosuppressive cyclophilin-binding cyclosporine, e.g., a compound of formula I and b) a co-agent. Co-agents include, but are not limited to, interferons, a conjugate of interferon, antiviral agents, helicase inhibitors, protease inhibitors, polymerase inhibitors and nucleoside analogs. The instant pharmaceutical combination may be used, e.g., in treating subjects having a flaviviridae infection, e.g., a Hepatitis C infection.Type: GrantFiled: December 20, 2005Date of Patent: March 1, 2011Assignee: Novartis AGInventors: Kai Lin, Beat Weidmann
-
Patent number: 7879322Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat disease related to bone abnormalities such as osteoporosis. An embodiment of the invention herein provides an antibody or a functional protein comprising an antigen-binding portion of said antibody for a target in sclerostin polypeptide, characterized in that the antibody or functional protein specifically binds to sclerostin polypeptide and can increase at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal.Type: GrantFiled: October 10, 2008Date of Patent: February 1, 2011Assignee: Novartis AGInventors: Michaela Kneissel, Christine Halleux, Shou-Ih Hu, Beate Diefenbach-Streiber, Josef Prassler
-
Patent number: 7811767Abstract: The invention relates to the analysis and identification of genes that are up-regulated simultaneously in transplant rejection. This simultaneous up-regulation of genes provides a molecular signature to accurately detect transplant rejection.Type: GrantFiled: March 13, 2007Date of Patent: October 12, 2010Assignee: Novartis AGInventors: Friedrich Raulf, Pierre Saint-Mezard, Hai Zhang
-
Patent number: 7807155Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: August 4, 2005Date of Patent: October 5, 2010Assignee: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 7741338Abstract: The invention relates to the stabilization of poly-ene macrolides and to a particular macrolide obtained in crystalline form.Type: GrantFiled: July 6, 2009Date of Patent: June 22, 2010Assignee: Novartis AGInventors: Francois Navarro, Samuel Petit, Guy Stone
-
Patent number: 7732134Abstract: This invention provides methods to predict the degree of elevation of serum cholesterol levels in patients treated with immunosuppressive medication. This invention also provides treatment strategies based on these predictions and kits to carry out these methods.Type: GrantFiled: September 29, 2003Date of Patent: June 8, 2010Assignee: Novartis AGInventors: Sridhar Kudaravalli, Mihael Hristos Polymeropoulos, Rosarelis Torres, Curt Douglas Wolfgang